ctDNA measurement was used to track the disease course in two patients with Merkel cell carcinoma whose disease had progressed on pembrolizumab, a programmed cell death-1 (PD-1) inhibitor [165]. This evidence concerns the gene PDCD1 and Merkel cell skin cancer.